Drug intelligence / Profile preview

Hyaron

Development stage: Unknown
Lead developer: Dongkook Pharmaceutical
Administration: Intradermal, Subdermal

Overview

Hyaron is a non-stabilized hyaluronic acid-based dermal filler and mesotherapy product primarily used for skin rejuvenation and hydration. Developed by DongKook Pharmaceutical, it acts as a skin booster by replenishing the dermal extracellular matrix with sodium hyaluronate. Unlike highly cross-linked fillers used for deep structural volumization, Hyaron's formulation allows for high integration into the skin tissues, where it binds water molecules to enhance elasticity, improve moisture retention, and provide a subtle volumizing effect to fill fine wrinkles. It is typically administered via intradermal or subdermal injection and is widely utilized in aesthetic medicine for its ability to improve overall skin quality and radiance.

Brand names: Hyaron
Other names: Hyaron Prefilled InjectionHyaron Skin Booster

Beyond the preview

Go deeper on Hyaron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hyaron.

Explore the full profile